Shalini Shenoy

Medicine & Life Sciences

1. Cell Transplantation 100%
2. Sickle Cell Anemia 98%
3. Transplants 90%
4. Unrelated Donors 84%
5. Transplantation 79%
6. Tissue Donors 75%
7. Graft vs Host Disease 66%
8. Hematopoietic Stem Cell Transplantation 61%
9. Child 45%
10. Bone Marrow 44%
11. Pediatrics 40%
12. Peripheral Blood Stem Cells 36%
13. Alemtuzumab 33%
14. Allogeneic Cells 33%
15. Stem Cell Transplantation 32%
16. Fetal Blood 27%
17. Chimerism 26%
18. Thalassemia 25%
19. Hemoglobinopathies 23%
20. Immune Reconstitution 22%
21. Siblings 21%
22. Peripheral Blood Stem Cell Transplantation 20%
23. Stem Cells 17%
24. Graft Rejection 17%
25. Chronic Granulomatous Disease 16%
26. fludarabine 16%
27. Survival 16%
28. Melphalan 16%
29. Rituximab 15%
30. T-Lymphocytes 15%
31. Autoimmune Lymphoproliferative Syndrome 14%
32. Safety 14%
33. Dyskeratosis Congenita 13%
34. Therapeutics 13%
35. Hematologic Neoplasms 13%
36. Acute Myeloid Leukemia 12%
37. Primary Immunodeficiency Diseases 12%
38. Clinical Trials 12%
39. Granulocytes 12%
40. Mortality 12%
41. Immunosuppression 12%
42. B-Lymphocytes 11%
43. Mucopolysaccharidosis I 11%
44. Abatacept 11%
45. Progression-Free Survival 11%
46. Hydroxychloroquine 11%
47. Bone Marrow Transplantation 11%
48. Neutrophils 10%
49. beta-Thalassemia 10%
50. Granulocyte Colony-Stimulating Factor 10%